LEADER 04313nam  2200493   450 
001 9910807290903321
005 20230807193821.0
010   $a1-68108-076-1
035   $a(CKB)3710000000495264
035   $a(EBL)4412614
035   $a(MiAaPQ)EBC4412614
035   $a(EXLCZ)993710000000495264
100   $a20160614d2015      uy|            0
101 0 $aeng
135   $aur|n|---|||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 00$a"Topics in anti-cancer research."$hVolume 4 /$feditors, Atta-ur-Rahman, FRS, Kings College, University of Cambridge, Cambridge, UK & Khurshid Zaman, Bentham Science Publishers, USA
210  1$aSharjah :$cBentham Science Publishers, Limited,$d[2015]
215   $a1 online resource (817 p.)
225 1 $aTopics in Anti-Cancer Research ;$vv.1
300   $aIncludes index.
311   $a1-68108-077-X 
327   $aCONTENTS; FOREWORD ; List of Contributors ; Targeted Cancer Therapy: The Roles Played by Antibody-Drug and Antibody-Toxin Conjugates ; 1. INTRODUCTION; 2. IMMUNOTOXINS; 2.1. Pseudomonas Exotoxin-Based Immunotoxins; 2.2. Pseudomonas Exotoxin-Based ITs in Treating Solid Tumors; 2.3. Diphtheria Toxin-Based Immunotoxins; 2.4. Ribosome Inactivating Proteins-Based Immunotoxins; 2.4.1. Ricin; 2.4.2. Recombinant constructs of RIP I toxins; 2.5. Ribonucleases-Based IT; 2.6. Proapoptotic Proteins Used As Targeted Immunotoxins/Chimeric Proteins; 2.7. Current & Future Developments of ITs
327   $a3. ANTIBODY-DRUG CONJUGATES 3.1. DNA Interacting Agents-Calicheamicins; 3.2. DNA Interacting Agents-Duocarmycins; 3.3. DNA Interacting Agents-Pyrrolo[1,4]Benzodiazepines; 3.4. Tubulin Interacting Agents-Auristatins; 3.5. Tubulin Interacting Agents-Maytansinoids; 3.6. Other Anticancer Drugs Conjugated to mAbs; 4. CURRENT AND FUTURE DEVELOPMENTS OF ADC ; DISCLOSURE; CONFLICTS OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Targeting Cell Surface Nucleolin in Cancer ; INTRODUCTION; CELL SURFACE LOCALIZATION OF NCL; LIGANDS OF CELL SURFACE NCL
327   $aCELL SURFACE NCL-DEPENDENT LIGAND SPECIFIC INTERNALIZATIONCELL SURFACE NCL AND SIGNALING COMPLEXES; TARGETING CELL SURFACE NCL; CELL SURFACE NCL AS BIOMARKER FOR CANCER; PATENTS RELATED TO NCL; CURRENT & FUTURE DEVELOPMENTS; DISCLOSURE; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Anticancer Agents Targeting Tubulin ; 1. INTRODUCTION; 2. MICROTUBULE DESTABLIZERS; 2.1. Colchicine; 2.2. Combretastatin A-4 (CA-A4); 2.3. Chalcones; 2.4. Phenstatins; 2.5. Podophyllotoxin; 2.6. Vinca Alkaloids; 2.7. Other Tubulin Polymerization Inhibitors; 3. MICROTUBULE STABLIZERS; 3.1. TaxolŽ
327   $a3.2. Other Tubulin Depolymerization InhibitorsDrugs Bind to Microtubule-Associated Proteins (MAPs); Peripheral Neuropathy Induced by Anti Mitotic Agents [177]; Role of ?-Tubulin Isotypes in Drug Binding [178]; 4. RECENT PATENTS; 4.1. Research Corporation Technologies Patents; 4.2. Brandeis University Patents; 4.3. Tuse et al. Patents; 4.4. Pinney et al.  Patents; 4.5. Aventis Pharma Patents (2001); 4.6. Davis et al. Patents; 4.7. Aventis Pharma Patents (2003); 4.8. Chang et al. Patents; 4.9. Hadfield et al. Patents; 4.10. Rigel Pharmaceuticals Patents; 4.11. NIH Patents
327   $a4.12. Cytopia Pty Ltd Patents4.13. Galemmo et al. Patents; 4.14. Pettit et al. Patents; 4.15. Patent by Aneja et al.; 4.16. Wyeth Holding Corporation Patents; 4.17. Champions Biotechnologypatents; 4.18. Bionomics Ltd. Patents; 4.19. Janssen Pharmaceutica Patents; 4.20. Exonhit Patents; 4.21. Centre National De La Recherche Scientifique Patents; 4.22. Development Centre of Biotechnology Patents; 4.23. Y M Biosciences Pty Ltd. Patents ; 4.24. Patents by Gangjee et al.; 4.25. Thorson et al. Patents; 4.26. Bionomics Ltd. Patents ; 4.27. Chen et al. (2014); 4.28. Wang et al. (2014)
327   $a4.29. Burns et al. (2014)
410  0$aTopics in Anti-Cancer Research
606   $aCancer$xResearch
606   $aCancer$xPrevention
615  0$aCancer$xResearch.
615  0$aCancer$xPrevention.
702   $aAtta-ur-Rahman
702   $aZaman$b Khurshid
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910807290903321
996   $aTopics in anti-cancer research$94061793
997   $aUNINA